Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Thu 21 Nov 2002, 18:03 Forim - Interim Results For The Six Months Ended 3
Forim - Interim Results For The Six Months Ended 31 August 2002 
Release Date: 21/11/2002 17:28:01      Code(s): FOM 
Forim - INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 AUGUST 2002                 
Forim Holdings Limited                                                          
   (Incorporated in the Republic of South Africa)                               
(Registration number 1986/004111/06)                                         
   Share code FOM     ISIN ZAE000002689                                         
   ("Forim" or "the group" or "the company")                                    
INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 AUGUST 2002                         
Group Income Statement                                                       
                                            Six months   Six months       Year  
                                                 ended        ended      ended  
                                                31 Aug       31 Aug     28 Feb  
2002         2001       2002  
                                             unaudited    unaudited    audited  
                                               R`000`s      R`000`s    R`000`s  
Turnover                                       104 034       95 304    193 262  
Operating profit before amortisation             4 609        3 907      4 281  
Amortisation of patents, trademarks                                             
 and goodwill                                      750          746      1 500  
Operating profit                                 3 859        3 161      2 781  
Finance income                                     114           53        161  
Finance costs                                   (1 179)      (1 192)    (2 428) 
Profit before taxation                           2 794        2 022        514  
Taxation                                         1 175          710        719  
Profit after taxation                            1 619        1 312       (205) 
Profit attributable to minority shareholders      (862)        (668)      (140) 
Net profit/(loss) attributable to shareholders     757          644       (345) 
Shares in issue (000`s)                         50 000       50 000     50 000  
Earnings/(loss) per share (cents)                  1,5          1,3       (0,7) 
Headline earnings per share (cents)                2,4          2,2        1,2  
Reconciliation between earnings                                                 
 and headline earnings                                                          
Attributable earnings                              757          644       (345) 
Amortisation of goodwill                           460          460        920  
Headline earnings                                1 217        1 104        575  
   GROUP BALANCE SHEET                                                          
31 Aug       31 Aug     28 Feb  
                                                  2002         2001       2002  
                                             unaudited    unaudited    audited  
                                               R`000`s      R`000`s    R`000`s  
Assets                                                                          
Property, plant and equipment                   33 089       32 444     33 488  
Pharmaceutical registrations,                                                   
 patents and trademarks                         29 197       31 760     29 947  
Deferred taxation                                  305           44        305  
Financial assets                                   379          379        379  
Current assets                                  83 811       75 542     74 406  
  Inventories                                   41 806       34 740     37 119  
Trade and other receivables                   35 812       33 759     32 551  
  Taxation                                         766          386      1 326  
  Cash and cash equivalents                      5 427        6 657      3 410  
Total assets                                   146 781      140 169    138 525  
Equities and liabilities                                                        
Shareholders` interest                          55 014       55 879     54 257  
Non-current liabilities                         37 544       37 838     36 331  
  Equity minority interest in subsidiaries      32 806       32 473     31 945  
Interest bearing                               3 338        4 277      2 986  
  Deferred taxation margin                       1 400        1 088      1 400  
Current liabilities                             54 223       46 452     47 937  
  Interest bearing borrowings                    2 151        2 595      2 722  
Taxation                                       1 111          253        476  
  Trade, payables and other provisions          41 746       34 215     35 468  
  Bank overdraft                                 9 215        9 389      9 271  
Total equity and liabilities                   146 781      140 169    138 525  
Net asset value per share (cents)                110,0        111,8      108,5  
   Group CASH FLOW STATEMENT                                                    
                                            Six months   Six months       Year  
                                                 ended        ended      ended  
31 Aug       31 Aug     28 Feb  
                                                  2002         2001       2002  
                                             unaudited    unaudited    audited  
                                               R`000`s      R`000`s    R`000`s  
Cash flows from operating activities             3 210        4 608      4 287  
Cash flows from investing activities              (918)      (2 990)    (4 921) 
Cash flows from financing activities              (219)         561       (316) 
Net increase/(decrease) in                                                      
cash and cash equivalents                       2 073        2 179       (950) 
Cash and cash equivalents/                                                      
 (overdrafts) at beginning of period            (5 861)      (4 911)    (4 911) 
Cash and cash equivalents/                                                      
(overdrafts) at end of period                  (3 788)      (2 732)    (5 861) 
   STATEMENT OF CHANGES IN EQUITY                                               
                                                     Non-                       
                                                distribu-  Distribu-            
Share      Share      table      table             
                           capital    premium   reserves   reserves      Total  
                           R`000`s    R`000`s    R`000`s    R`000`s    R`000`s  
Balance at 1 March 2001        500     23 257        450     30 395     54 602  
Net loss for year                                              (345)      (345) 
Transfer from/(to) non-                                                         
 distributable reserve                               (45)        45          -  
Balance at 28 February 2002    500     23 257        405     30 095     54 257  
Net profit for period                                           757        757  
Transfer from/(to) non-                                                         
 distributable reserve                               (22)        22          -  
Balance at 31 August 2002      500     23 257        383     30 874     55 014  
NOTES                                                                           
1. Financial review                                                             
   The major activities of the group are conducted by its listed subsidiary,    
Alliance Pharmaceuticals Limited ("Alliance"), which manufactures, markets and  
distributes generic pharmaceuticals, medical and surgical disposables,          
parenteral nutrition and consumer personalcare products. Shareholders are       
referred to the announcement of Alliance`s audited results for the six months   
ended 31 August 2002, published simultaneously with this announcement.          
In addition, the group continues to own properties situated in and around the   
Johannesburg Central Business District.                                         
   Turnover increased by 9,2% over the same period last year. Earnings per share
amounted to 1,5 cents for the current period compared to 1,3 cents for the same 
period the previous year and headline earnings per share increased to 2,4 cents 
from 2,2 cents for the same period the previous year.                           
   The calculation of headline earnings per share is based on 50 000 000 shares 
in issue and attributable earnings for the interim period of R1 216 839 (2001:  
R1 104 073) before amortisation of goodwill of R459 834 (2001: R459 834).       
It is anticipated that the results for the second six months of the year will   
continue to show an improvement on those of the previous year.                  
   The interim financial statements have been prepared on the historical cost   
basis and in accordance with South African Statements of Generally Accepted     
Accounting Practice. The accounting policies applied are consistent with those  
applied in the annual financial statements for the year ended 28 February 2002. 
2. Independent review by the auditors                                           
The interim report has been the subject of a review by the company`s         
auditors, Grant Thornton Kessel Feinstein, who have performed this review in    
accordance with the guideline "Guidance for Auditors on Review of Interim       
Financial Information" issued by The South African Institute for Chartered      
Accountants.                                                                    
   A copy of their unqualified review report is available for inspection at the 
registered office of the company.                                               
3. Dividends                                                                    
It is the company`s policy to consider a dividend at the end of each         
financial year.                                                                 
4. Cautionary announcement                                                      
   Shareholders are referred to the cautionary announcement published in the    
press on 7 October 2002 and are advised that negotiations are continuing for the
sale of certain of the group`s fixed property.  Shareholders are advised to     
continue to exercise caution when dealing in the company`s securities until a   
further announcement is made.                                                   
For and on behalf of the board                                                  
  H R Levin                          M Gelbart                                  
  Chairman                           Managing Director                          
22 November 2002                                                                
Directors: H R Levin* (Chairman), M Gelbart (Managing), Y Bhayat*,              
           J E Forman (*non-executive)                                          
Transfer Secretaries: Computershare Investor Services Limited,                  
                      Ground Floor, 70 Marshall Street, Johannesburg, 2001      
(PO Box 1053, Johannesburg, 2000)                         
Company Secretary: Executive Secretarial Services CC,                           
                   PO Box 261269, Excom, 2023                                   
Date: 21/11/2002 05:28:00 PM Produced by the JSE SENS Department                

Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
[  Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: